Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Regeneron Pharmaceuticals (REGN)

Regeneron reports preliminary 2024 sales of $6 billion, up 1%; $14 million Q4 charge

Mixed Impact 3 of 5 earnings Written later

Regeneron released preliminary, unaudited fourth-quarter and full-year 2024 figures at the J.P. Morgan Healthcare Conference, showing aggregate U.S. EYLEA net product sales of $6 billion for the year, up 1%. The company also expects a fourth-quarter acquired in-process R&D charge of approximately $14 million pre-tax, which it says will reduce GAAP and non-GAAP net income per diluted share by about $0.11, and notes that results have not been finalized.

Key points

  • EYLEA HD and EYLEA aggregate U.S. net product sales were $6 billion for 2024, up 1%, and $1.5 billion in the fourth quarter of 2024 (preliminary, unaudited).
  • Expected fourth-quarter 2024 acquired IPR&D charge of approximately $14 million pre-tax, primarily related to asset acquisitions.
  • The charge is expected to lower GAAP and non-GAAP net income per diluted share for Q4 2024 by approximately $0.11.
  • Libtayo exceeded $1 billion in 2024 annual net sales, according to the press release.

The filing

CompanyRegeneron Pharmaceuticals (REGN)
Form8-K, current report
Filed with the SECJan 13, 2025, 6:37 AM ET
Accession number0001104659-25-002826

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 13, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.